← All trials
NCT00130208
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2005
- Primary completion
- Jan 1, 2008
- Completion date
- Feb 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- KeryxLead sponsor
- Rush UniversityStudy director
- University of GroningenOverall official - principal investigator
- Hebrew UniversityOverall official - principal investigator
- Monash UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.